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psychological treatments in clinical trials:
evidence from a review of NIHR-funded trials
Conor Duggan1,2*, Glenys Parry3, Mary McMurran4, Kate Davidson5 and Jane Dennis6Abstract
Background: There is a concern in the literature that harm from interventions is insufficiently documented in
clinical trials in general, and in those assessing psychological treatments in particular. A recent decision by a trial
steering committee to stop recruitment into a randomized controlled trial (RCT) of a psychological intervention for
personality disorder led to an investigation of the recording of harm in trials funded by the National Institute for
Health Research (NIHR).
Methods: The protocols and final reports of all 82 NIHR trials funded between 1995 and 2013 were examined for
the reporting of adverse events. These were subdivided by category of intervention.
Results: None of the psychological intervention trials mentioned the occurrence of an adverse event in their final
report. Trials of drug treatments were more likely to mention adverse events in their protocols compared with those
using psychological treatments. When adverse events were mentioned, the protocols of psychological interventions
relied heavily on severe adverse events guidelines from the National Research Ethics Service (NRES), which were
developed for drug rather than psychological interventions and so may not be appropriate for the latter.
Conclusions: This survey supported the belief that the reporting of adverse events in psychological treatments is
weak and the criteria used may not be appropriate. Recommendations are made as to how current practice
might be improved.
Keywords: Harm, Adverse events, Psychological interventions, Clinical trialsBackground
During 2012, the Data Monitoring Committee (DMC)
of a publicly funded trial of a psychoeducation with
problem-solving (PEPS) intervention for community-
dwelling adults with personality disorder [1] noted higher
rates of adverse events (AEs), specifically mental health-
related adverse events (overdose, self-harm and suicide
attempts), among those in the active arm of the interven-
tion. The DMC, who examined unblinded data, alerted
the Trial Steering Committee (TSC), whose role is inde-
pendent trial oversight. The TSC were unable to rule out
the possibility that the intervention was instrumental in* Correspondence: Conor.Duggan@Nottingham.ac.uk
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unless otherwise stated.the excess of AEs and so the TSC issued an instruction
to stop recruitment into the trial. To our knowledge,
this was the first time recruitment to a UK trial of a
psychological therapy had been stopped on the grounds
of adverse events.
While there is recognition that harm might arise from
psychological interventions in the training of those who
provide psychological therapies [2] and in the theoretical
psychotherapy literature [3], many believe that this is
neglected in both research and the actual practice of
psychotherapy. Several commentators have criticized, for
instance, the assumption that as psychotherapy is only
talking, the focus has been on its benefits rather than on
the harm that it might cause [4,5]. Parry [6] has argued
that the increasing recognition that psychological inter-
ventions can be effective might also lead to a parallel
recognition of the harm that they may cause. Othersl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Duggan et al. Trials 2014, 15:335 Page 2 of 9
http://www.trialsjournal.com/content/15/1/335have contrasted the scrutiny which is applied to medica-
tion, where adverse monitoring is mandatory, with evalu-
ation of psychotherapy [5]. Although there is growing
interest in this issue [7,8], it nonetheless does not ap-
pear to affect the recording of harm (or lack thereof ) in
clinical trials that assess psychological interventions.
This review examines the recording of AEs in trials of
psychological treatments in a particular funding stream,
namely the Health Technology Assessment (HTA) pro-
gram of the UK’s National Institute of Health Research
(NIHR), and makes some recommendations to improve
practice in the recording of such events in future trials.
Adverse events and harm
We define ‘harm’ (in which an adverse event is a particular
instance) as a sustained deterioration that is caused dir-
ectly by the psychological intervention (Figure 1). The fact
that the deterioration has to be sustained addresses the
concern that some temporary discomfort is often a neces-
sary part of the process of psychological change [9].
It is also important to establish a causal connection
between the intervention and the subsequent deterior-
ation, as the latter may be due to other causes (for ex-
ample, a part of the natural history of the condition or a
response to troubling life events). For instance, when a
depressed suicidal patient commits suicide despite being
in treatment, it would be wrong to automatically assume
that the treatment was responsible. While the distinctionA Typology
Harm
1. Sustained deterioration
2. Caused by the psychological
intervention
a
1
2
3
4
b
1)
2)
Figure 1 A definition of harm from a psychological intervention togebetween harm being caused by the intervention or being
part of the natural course of the disorder or due to life
events is probably impossible in an individual case, the
design of a randomized trial permits consideration of
this possibility when there is a differential effect between
the trial and the control condition. Lilienfeld [7] makes
use of the importance of trial evidence by making it a
further criterion in establishing harm arising from a psy-
chological intervention, namely that the harm has been
replicated in a number of good quality clinical trials
using the intervention, but he recognizes the ethical dif-
ficulty in setting up a clinical trial to replicate an iatro-
genic effect. Consequently, we have not included that in
our definition of harm.
The second consideration is how harm is measured
(illustrated in the second column in Figure 1). There are
two sources of evidence: subjective and objective, with
both subdivided into that which is reported by self and
others. The objective measures could comprise both
patient-reported outcomes using psychometrically valid
and reliable instruments and clinician-rated objective
measures. These subdivisions illustrate the complexity
of the area if the assessment of harm is to capture the
multiple domains of an individual’s functioning and where
a perceived benefit to one party may not always shared
by others (such as in couples therapy). Similarly, self-
reported improvement and satisfaction with the treatment
does not always accord with improvement assessed by of Harm
Measured by
) Effect on Self
) Increase in symptoms 
or development of new 
symptoms
) Behavioural 
deterioration
) Increased dependency
) Other
) Effect on Others
1) Spouse/Partner
2) Family
3) Friends
4) Other
Produced by
Subjective Report
Objective Report
Increase in Mortality
Increase in Re-offending 
etc.
1) Inappropriate 
treatment
2) Inappropriate 
application of an 
appropriate 
treatment 
3) Patient 
characteristics 
e.g. Alexithymia
etc.
ther with its measurement and etiology.
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when rated objectively by outside assessors. We make a
distinction between perceived harm and that defined
through objective measurement.
Third, there is a process question - how has this harm
occurred (third column in Figure 1)? We divide this into
a simple trichotomy of being caused by: (a) the treatment,
(b) the application of the treatment, or (c) patient-related
factors. In (a), harm may have been caused directly by
using an inappropriate treatment which results in clinical
deterioration, or when an ineffective treatment for an indi-
vidual’s condition is chosen despite a more effective option
being available (the potential to cause harm by withhold-
ing or delaying a beneficial treatment). In (b), harm may
arise when an otherwise effective intervention has been
inappropriately applied. This is especially important for
psychological treatments where the competence and nat-
ural attributes of the therapist assume greater importance
compared to those of a practitioner prescribing a drug
[10]. Finally (c), where attributes of the patient may render
an appropriate treatment applied by a competent therapist
ineffective. For instance, it is recognized that while relax-
ation treatment may be helpful to some who suffer from
panic attacks, for others, its focus on interoceptive stimuli
can have the effect of precipitating attacks [11]. Thus,
an intervention may be effective overall but be harmful
to a minority.
We illustrate the utility of this harm matrix by applying
it to the findings from the Cambridge Somerville Youth
Trial, in which matched delinquent youths were subse-
quently randomized either to the active treatment condi-
tion (a supportive counselling intervention that continued
for five years) or to whatever was available from current
services [12]. When those in the trial were followed up
30 years after its completion, it was found that while there
was no benefit from the active treatment in 59% of the
matched pairs, in the 41% where there were differences,
those with the worse outcomes across a range of measures
had been in the active treatment condition [13]. These in-
cluded increases in mortality, rates of mental disorder and
alcoholism, re-offending and lower levels of occupational
attainment. The range of outcomes and the long time
frame strongly indicate that those in the active arm of the
trial had suffered sustained harm. This was in spite of the
fact that both the children and their parents in the active
arm had expressed their appreciation of the help that had
been provided by their counsellors. It was also argued that
the deterioration had been caused by the intervention as
those that fared worst had received the most help (there
was a dose response relationship), and were children of
the most compliant parents [13]. The trial was also im-
portant in that its investigators sought to provide a
mechanism to explain this unexpected finding. Although
various possibilities were considered, such as the raisingof expectations that were unsustained once the inter-
vention was withdrawn, and ‘deviancy training’ where
the more delinquent youth had a detrimental influence
on their more vulnerable peers while they were together
at summer camp [14], the cause of this adverse outcome
has proved to be elusive [15]. This highlights one of the
major problems in this area, namely, that it is difficult to
be sure why harm has occurred, even when harm has been
established.
Adverse events in clinical trials
We define an adverse event as harm occurring within a
trial where there is at least an assumption of causality.
This may have been anticipated (and therefore identified
within the protocol of the trial) or unanticipated - the
latter being some untoward occurrence that requires
attention even though it was not noted in the original
protocol. Often, interventions are offered to vulnerable
individuals and one ought not to be surprised if unto-
ward outcomes occur. Here, a randomized design assists
in clarifying the issue as the crucial distinction is that
the differential rate of untoward outcomes can be assessed
between the active and control condition.
The difficulties in defining an adverse event (particu-
larly in establishing causality) are acknowledged. For
instance, in an update of the CONSORT statement to
improve the reporting of harm, Ioannidis et al. [16]
write: ‘In a typical randomized trial, it is difficult to
know whether an observed event is partially or entirely
due to the intervention or whether it is totally unrelated
to the intervention. The purpose of the trial is to collect
and appropriately report good and bad events and out-
comes so that they may be compared across treatment
groups. In this respect, the term “adverse events” is
probably better to describe harmful events that occur
during a trial’ (p. 782). Serious adverse events are de-
fined as ‘…reactions which, in their most severe forms,
threaten life or function. Such reactions should be
promptly reported to regulators’ ([16], p. 782).
This focus on the safety of the intervention requires
that any specified adverse events, along with any serious
unexpected untoward events, must be recorded and re-
ported by the Chief Investigator to a range of bodies -
the Research Ethics Committee, the TSC, and the DMC.
Of these, only the DMC has access to unblinded data
and is required to provide an independent review and
recommendations in the light of potential treatment
adverse effects. The DMC must then make a decision on
whether to inform the TSC. It is the TSC that has the
responsibility to recommend discontinuation of the study
if significant ethical or safety concerns arise or if there is
unequivocal statistical evidence of benefit prior to the
completion of the study. However, these decisions are
rarely straightforward, and there is a different threshold
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the case of benefit [17]. In the PEPS trial, the TSC recom-
mended that recruitment and treatment of participants
should cease due to the excess number of adverse events
relating to mental health in the active treatment arm of
the trial, although the trial should continue to collect
follow-up data on all of those who had already completed
treatment.
One other contentious issue is whether non-completion
of treatment (also known as leaving early, premature ter-
mination or dropout) ought to be considered an adverse
event. The reasons for dropping out are heterogeneous
and some reviews have considered drop out as an adverse
event [18].
The reporting of adverse events in clinical trials of
psychological interventions
The recognition that the reporting of harms in randomized
controlled trials is unsatisfactory led to the CONSORT
group suggesting 10 new recommendations in the report-
ing of harms [16]. These included: more comprehensive
definitions of harm and how this will be monitored to be
stated in the Method; reporting of any discontinuation or
reduction of dosage during the study; if no adverse events
are recorded, then this should be explicitly acknowledged
within the Results; and, finally, a balanced appraisal of
the benefits and risks of the intervention to be provided
in the Discussion.
Despite these injunctions, there remain inadequacies
of adverse event reporting in non-pharmacological inter-
ventions in general and particularly in mental health tri-
als. Ethgen et al. [19] showed that in the reporting of
harms, withdrawals due to adverse events and severity
were more frequent in pharmacological compared with
non-pharmacological treatments in rheumatoid arthritis
and osteoarthritis. In mental health, the reporting of harm
in drug trials was adequate in only 21.4% of the trials
reviewed but none of the non-drug trials had adequate
reporting of clinical adverse events [20].
We examined the reporting of adverse events in recent
trials of psychological treatments for those with person-
ality disorder (a similar patient population to PEPS). Of
39 trials for antisocial (ASPD) and borderline personality
disorder (BPD), Gibbon et al. [21] found only one out of
11 studies mentioned adverse events for ASPD, and Stoffers
et al. [22] found none for BPD. Jonsson et al. [23], in a
recent review, reported that only 21% of randomized
controlled trials of psychological intervention had infor-
mation suggesting that harm was monitored.
We investigated this issue in trials funded by the
National Institute of Health Research (NIHR), the main
public funder of psychological therapy trials in the UK.
Our objectives were: (a) to discover whether PEPS is the
first such trial to be discontinued for this reason, (b) toreport the extent to which adverse events are specified
in psychological therapy trial protocols, and (c) reported
in trial reports.
Method
On request, NETSCC (NIHR Evaluation, Trials and Studies
Coordinating Centre) sent the investigators a list of all
studies funded between August 1995 and October 2013.
There were 102 studies: 85 funded by the HTA, 10 by
Public Health Research (PHR), 5 by Efficiency and Mech-
anism Evaluation (EME) and 2 by the Public Services and
Delivery Research (PS & DR) programs. Studies that in-
volved a clinical evaluation of any kind were included.
This comprised 91 studies, which included all 85 which
were funded through the HTA program, 5 by the EME
program and 1 by the HS & DR program. These com-
prised pharmacological, psychological and other inter-
ventions for mental health (71%) and other physical
conditions (such as diabetes and obesity). Of these, nine
were excluded, either because they were not trials (for
example epidemiological surveys) or because there was
insufficient information available for their inclusion.
We divided these 82 trials into four groups: (a) completed
trials with a final report and protocol, (b) completed trials
with a final report but without a protocol, (c) incomplete
trials which had been recently funded and where only the
protocols were available, and (d) incomplete trial reports in
the editorial stage (again, where only the protocols were
available as the final report is awaited, see Figure 2.)
The trials were subdivided into those which were
(a) psychological only, (b) drug only, (c) a combination
of psychological and drug, and (d) other (such as occu-
pational therapy, physiotherapy or case management).
These 82 reports were searched manually by the first
author and any information on adverse events from either
the protocol and/or final reports (where available) was
extracted and summarized.
Results
In the 82 trials, 28 trials had been published with a final
report; 14 of these had protocols available but another
14 did not. For the latter we relied on the published re-
port only. Of the remaining 54 trials, 47 were still in
progress and another 7 were in the process of being
published so that for these only the protocols were avail-
able for examination. A total of 44 of the interventions
were psychological, 14 involved drugs, 5 were a combin-
ation of drugs and a psychological intervention and 19
were other (see Table 1).
Completed studies
We found no evidence of a trial having been discontin-
ued because of adverse event reports prior to PEPS. Spe-
cifically, none of the trials using a psychological treatment
Complete with 
protocols
n=14
Complete, no 
protocol
n=13
Incomplete, 
protocol only
n=48
Complete, protocol 
only (in editorial)
n=7
Registered studies 
Aug 1995-Oct 2013
n=102
Clinical evaluations
n=91
Trials
n=82
Not clinical 
evaluations 
n=11
Not trials or insufficient 
information
n=9
Figure 2 Flow diagram of included and excluded trials from the NIHR database.
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none of the 14 completed studies using a psychological
intervention was there a mention of an adverse event.
Conversely, there was some reporting of adverse events
in the final reports of each of the other categories.
Incomplete studies
In the incomplete trials and those at the editorial stage,
we found that psychological interventions (55% of the
total) mentioned adverse events in 17 of the 30 trial pro-
tocols (56%). In contrast, drug interventions (together
with drug and psychological interventions combined)
mentioned adverse events in all of the 9 protocols exam-
ined. We noted, however, that in the more recently funded
psychological studies that adverse events were more likely
to be mentioned in their protocols.
In summary, none of the psychological interventions
mentioned adverse events in their final reports and wereTable 1 Recording of adverse events (AEs) from 82 NIHR-fund
Num
Proto
Completed studies with protocols Number of protocols 14
Number with AEs 5
AEs in final report 3
Completed studies without protocols Number of final reports 13
Number with AEs 1
Incomplete studies (protocols only) Number of protocols 48
Number with AEs 31
Incomplete studies
(in editorial, protocols only)
Number of protocols 7
Number with AEs 4 (50
Results from survey of 82 NIHR-funded trials.less likely to list adverse events in their protocols com-
pared with drug trials but this difference is changing
with the more recently funded psychological trials at
least mentioning adverse events in their protocol.
Looking specifically at how adverse events were recorded
in the protocols of these trials of psychological interven-
tions, there appeared to be two approaches. The first was
for these not to be considered at all, or for the likelihood of
their occurrence to be dismissed. For instance, one finds
such comments as ‘There is no evidence that CBT is harm-
ful. IAPT therapists are experienced in conducting risk as-
sessment’ and ‘No adverse events or serious adverse events
will be recorded or reported in this study’. Alternatively,
when adverse events were reported there was a reliance on
the definitions of severe adverse events from the safety
reporting guidelines from the National Research Ethics
Service (NRES). Here, a severe adverse event is one which:
(a) results in death, (b) is life threatening, (c) requiresed trials subdivided by types of intervention
ber of
cols
Psychological
Treatments
Drug
Treatments
Combined Other
7 3 2 2
2 (28%) 1 (33%) 1 (50%) 1 (50%)
0 1 1 1
7 2 1 3
0 0 0 1 (33%)
28 8 2 10
17 (61%) 8 (100%) 2 (100%) 5 (50%)
2 1 0 4
%) 0 1 (100%) 0 3 (75%)
Duggan et al. Trials 2014, 15:335 Page 6 of 9
http://www.trialsjournal.com/content/15/1/335hospitalization or prolongation of existing hospitalization,
(d) results in persistent or significant disability, (e) consists
of congenital abnormality or birth defect or (f) is otherwise
considered medically significant by the investigator. When
adverse events are listed in the protocols of psychological
interventions, one can see the influence of NRES, with
death occurring in 65%, hospitalization in 56%, persistent
disability in 43%, and congenital abnormality or birth de-
fect in 39%. Other events that one might consider rele-
vant for psychological therapies (such as self-harm,
symptom change, distress or attendance at Accident &
Emergency departments) were mentioned in only a few
trials.
Discussion
Randomized controlled trials provide the best opportun-
ity to examine the recording of adverse events as data
are more likely to be systematically recorded compared
with routine clinical practice, and their design allows
one to draw causal inferences between an intervention
and any harmful outcome [8]. They therefore offer an
opportunity, not only to identify and thereby avoid using
interventions that might be harmful, but also to provide
information about possible mechanisms whereby psy-
chological interventions can effect change.
There is substantial evidence that some patients may be
harmed by psychological therapy, although the prevalence
and causes of harm have been inadequately researched
([24], p. 206). Indications of potential harm are adverse
events, deterioration in mental state and the patient’s
perceptions of having been adversely affected. This study
focused on the first of these indicators, adverse events,
which one would expect to be routinely recorded and re-
ported in well-conducted randomized controlled trials.
However, our examination of the literature suggests that
unfortunately such events are not being adequately re-
ported. The failure to specify, record and report adverse
events during psychological therapy was confirmed by our
examination of 91 NIHR-funded trials.
This absence of reporting could mean that no adverse
event occurred (a zero event), that it occurred but it was
either not recognized or recorded, and finally, that it
was recorded but not reported. Current practice, regret-
tably, does not allow one to distinguish between these
alternatives.
Of the 37 psychological trial protocols examined, 17
(46%) did mention adverse events, but used the definitions
of adverse events suggested by the NRES, for example
death, hospitalization or persistent disability. There was
little evidence of thought being given to which adverse
event might be likely to arise from a specific intervention
in a particular population. For example, people with
borderline personality disorders may be at increased risk
of negative outcomes from psychological therapy [25] andwhilst some hospital attendance for minor self-harm is
characteristic of this population, life-threatening self-harm
and relationship breakdown could be considered adverse
events.
An example of how defining therapy-specific adverse
events could be achieved is provided by Horigian et al.
[26] who produced some general principles and gave
some examples to help illustrate their definition. In their
trial of family therapy for drug abusing adolescents, for
instance, they did not consider an increase in drug use
to be an adverse event, arguing that drug use among
adolescents is so erratic that any increased usage would
be difficult to measure. Hence, it was only when such
increased drug use resulted in hospitalization that it was
categorized as a severe adverse event. In addition, they
recommended systematic monitoring so that general
and specific questions that target the relevant areas are
asked throughout the study at specified intervals. To
achieve comprehensive coverage of harm, experts in the
intervention, ethicists and medical safety officers were
all involved in adverse event definition and monitoring
during the development of the protocol for the trial.
Horigian et al. [26] also highlight a further issue which
requires attention: only some adverse events are spontan-
eously reported, and accurate assessment requires system-
atic monitoring, with the use of structured interviews and
records from other agencies. Horigian et al. [26] found
that only 30% of adverse incidents were spontaneously
reported to research assistants, but this increased to 70%
when structured interviews were used. This is consistent
with findings that psychotherapy patients are likely to hide
negative material in particular, and that even experienced
therapists are rarely able to detect this [27].
There was evidence of improvements over time, with
more recent trials more likely to specify adverse events
in protocols. Over the time period covered by this study,
there have been a number of developments in accepted
good practice in trial design and reporting, which take
time to filter through to protocols and even longer to
influence final reports. For example, the 2004 revision of
the CONSORT recommendations on harm monitoring
seems to have had little impact in our study sample. The
anticipated guidance on the reporting of complex ran-
domized controlled trials within CONSORT-SPI [28],
which we understand will include advice on the record-
ing of adverse events, is to be especially welcomed and
research funding agencies and trial investigators should
consider how to expedite its adoption.
The revised EU clinical trials directivea will govern
pharmacological trials, but is likely to influence the con-
duct of trials of psychological interventions in the UK
and continental Europe. The revisions aim to introduce
a simpler, risk-adjusted authorization procedure for trials
of medicines and medicinal products and simpler
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tions. Whilst it is unlikely that psychological interven-
tions would be included in such regulations in the
foreseeable future, bringing such reporting to an equiva-
lent standard would address many of the shortcomings
we identified in trial protocols and reports.
Before presenting recommendations, we need to con-
sider the limitations of this study. First, the small numbers
of trials in each group make it difficult to be confident that
the differences found between psychological and pharma-
cological trials, or between earlier and later protocols, are
robust. The number of earlier trials with no accessible
protocol was a result of the funding agency not insisting
that protocols were produced. This omission has now
been corrected so that all recent trials have a detailed
protocol. Despite these limitations, it is clear that there is
considerable room for improvement in specifying, record-
ing and reporting adverse events in NIHR-funded clinical
trials of psychological interventions. We therefore discuss
possible ways to address these shortcomings.
Firstly, trialists could report on the full range of scores
on the principal dependent variables distributed by quar-
tile or, for dichotomous variables, the number needed to
harm rather than the group mean, as it is likely that the
active treatment will increase the variance compared to
no treatment control [7]. Alternatively, or in addition,
investigators could report the proportion of patients
who deteriorate on clinical measures in both the experi-
mental and control groups. At an individual level, visual
inspection of the outliers in the fourth quartile may
identify those at risk of being harmed by the interven-
tion [8]. This recognition of an adverse effect of treat-
ment at an individual level is important as it allows an
identification of clinical deterioration in certain instances
even when the intervention overall has been successful.
Secondly, papers should explain how adverse events
were defined and recorded, and should report AEs for
treatment and control groups. If AEs have not been de-
tected then this should be stated explicitly in the results.
Investigators should describe the method they used to
determine whether or not adverse events are related to
the treatment intervention. Thirdly, investigators should
not rely on generic checklists but try to identify, by con-
sensus, adverse effects that could plausibly be related to
the effect of the intervention on the population being
studied. These include being informed by previous re-
search into the prevalence of the disorder, its natural
progression and symptomatology.
Fourthly, active and systematic methods should be
used to capture as complete a dataset as possible when
recording adverse events, in both treatment and control
groups, including structured interviews and use of service
utilization databases. Fifthly, whilst we have argued that
current practice suffers from insufficient recording ofadverse events when psychological interventions are eval-
uated in clinical trials, one must be careful not to err in
the opposite direction leading to the over-recording of
information. Already, commentators argue that the
regulatory framework for conducting large randomized
trials is already so burdensome that trials are very diffi-
cult and costly to carry out [29,30]. Given the multifa-
ceted consequences of psychological interventions
described in Figure 1, there is a temptation to develop a
long list of potential adverse effects that would be diffi-
cult to monitor and interpret. This needs to be resisted.
What is needed is a streamlined yet flexible list of events
that are meaningfully related to the condition and inter-
vention that are informed by the trialists’ expertise and
the patients’ needs. This will require thought and effort
from both parties and ought not to be seen as an add-on
to other aspects of the design of the investigation.
While clinical trials are difficult to carry out, their design
provides the most internally valid estimates of harmful ef-
fects [8]. Although there are difficulties in studying rare
events (such as harms) in trials with modest sample sizes
and other methods such as large N observational studies
and intensive process analysis are also required [31], only
a properly randomized comparison allows conclusions to
be drawn about the relative rates of adverse effects and
adverse events between interventions, as well as their
relative efficacy. If the reporting of negative outcomes
and adverse events in trials were improved, meta-analysis
would enable robust conclusions to be drawn about the
risks and benefits of psychological therapies
As Dimidjian and Hollon [8] point out, identification
of a harmful effect is only the first step; what is then re-
quired is an understanding of the mechanism to explain
such an effect (such as vicarious learning from a nega-
tive role model in group program for delinquents). Such
an understanding would not only lead to the avoidance
of harmful interventions, but also contribute to identifying
which psychological intervention works best for whom.
Conclusions
This study examined the reporting of adverse events
across a range of interventions in NIHR-funded trials
between August 1995 and October 2013. We found that
those involved in trialing psychological interventions
gave less attention to the reporting of adverse events
compared with trials of other types of interventions and
especially with drug interventions. Although this situation
is improving with more recently funded psychological tri-
als mentioning adverse events in their protocol, the types
of adverse events described are strongly influenced by cat-
egories from the NRES safety reporting standards which
have limited applicability for psychological interventions.
We conclude with some recommendations for the future
practice of recording and reporting adverse events in
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lar, we recommend less reliance on generic checklists,
but rather on events that could plausibly be related to
the condition being treated, given its natural progression
and symptomatology.
Endnote
aRegulation (EU) No 536/2014 of the European Parlia-
ment and of the Council of 16 April 2014 on clinical tri-
als on medicinal products for human use, and repealing
Directive 2001/20/EC.
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